Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease.
about
Pharmacoperone Identification for Therapeutic Rescue of Misfolded Mutant ProteinsDisease-associated mutations affect intracellular traffic and paracellular Mg2+ transport function of Claudin-16Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptorsPharmacological chaperoning: a primer on mechanism and pharmacologyExpanding the number of 'druggable' targets: non-enzymes and protein-protein interactionsPhenylketonuria: translating research into novel therapiesThe delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiologyEffects of pH and Iminosugar Pharmacological Chaperones on Lysosomal Glycosidase Structure and StabilityNew therapeutic approaches for Krabbe disease: The potential of pharmacological chaperonesAngiotensin I-converting enzyme Gln1069Arg mutation impairs trafficking to the cell surface resulting in selective denaturation of the C-domainTrafficking and quality control of the gonadotropin releasing hormone receptor in health and diseaseThe ataxia3 mutation in the N-terminal cytoplasmic domain of sodium channel Na(v)1.6 disrupts intracellular traffickingDominant-negative effect of SCN5A N-terminal mutations through the interaction of Na(v)1.5 α-subunitsHigh-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones.A phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptorRole of tyrosine 33 residue for the stabilization of the tetrameric structure of human cytidine deaminase.Conformational effects of Lys191 in the human GnRH receptor: mutagenesis and molecular dynamics simulations studies.Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs.Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.Salt bridge integrates GPCR activation with protein traffickingA single conserved leucine residue on the first intracellular loop regulates ER export of G protein-coupled receptors.Dominant negative effects of human follicle-stimulating hormone receptor expression-deficient mutants on wild-type receptor cell surface expression. Rescue of oligomerization-dependent defective receptor expression by using cognate decoys.Chaperoning G protein-coupled receptors: from cell biology to therapeuticsRegulation of G-protein coupled receptor traffic by an evolutionary conserved hydrophobic signal.Fabry disease - current treatment and new drug development.Using automated imaging to interrogate gonadotrophin-releasing hormone receptor trafficking and function.A single lys residue on the first intracellular loop modulates the endoplasmic reticulum export and cell-surface expression of α2A-adrenergic receptorDisease-associated mutations affect GPR56 protein trafficking and cell surface expression.Norepinephrine deficiency is caused by combined abnormal mRNA processing and defective protein trafficking of dopamine beta-hydroxylase.Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptorBiochemical mechanism of pathogenesis of human gonadotropin-releasing hormone receptor mutants Thr104Ile and Tyr108Cys associated with familial hypogonadotropic hypogonadismChemical and biological approaches synergize to ameliorate protein-folding diseases.Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1)Ligands for glaucoma-associated myocilin discovered by a generic binding assaySalt bridges overlapping the gonadotropin-releasing hormone receptor agonist binding site reveal a coincidence detector for G protein-coupled receptor activation.Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptorsRole of the intracellular domains of the human FSH receptor in G(alphaS) protein coupling and receptor expressionAssay strategies for identification of therapeutic leads that target protein traffickingEffects of cellular, chemical, and pharmacological chaperones on the rescue of a trafficking-defective mutant of the ATP-binding cassette transporter proteins ABCB1/ABCB4.Protein disulfide isomerase chaperone ERP-57 decreases plasma membrane expression of the human GnRH receptor
P2860
Q21131288-CBDFC88E-CCCA-4289-90D5-85DFD23CD93DQ24544268-AF2F1791-FCF6-444C-AF1A-B5F64BC3BB1CQ26992276-ECBAC392-8AB7-4EE2-880C-9EAC36ABA868Q27001695-8CD22843-05F5-42D5-895C-DC8E0EAFDC8AQ27003966-EE26C5A8-1E9D-409B-A3CC-583580BBE0D3Q27015749-F21C922F-7F74-4F1D-B2B8-9A253D8EE106Q27015793-8F9F1123-F980-4392-85B9-2CAF73BCEA0EQ27654912-C750C94D-AD80-4DAD-AC19-990C02652F81Q28068142-DC0285A3-796B-4C9B-A9CD-8FA190A2B5DFQ28473818-D0AAA58F-C760-45A1-A8EA-B48F9AAA1185Q28755163-A51C01AB-6CD7-44FD-8586-EE851677744FQ30487520-922A52CC-ED08-44F5-9A2B-BE861B4C9F67Q33161467-CC411E8C-EFC9-4BC0-BF05-694D82E3885FQ33275131-74E7CEEB-FECB-4125-9C7C-35C96CA54EDCQ33629937-E961BAE0-5879-4D4E-BA33-96BD422C0DDBQ33634754-9D799C5E-03D4-407C-9842-689DAD4DE6AFQ33693003-2F829C8D-D5D7-4C2E-A15C-7C09F6D9FE2AQ33699210-6BF46F40-9A8C-46F8-8A65-F404DEBD473DQ33717398-940CD52D-A735-44DA-A177-EA637E5FC254Q33732720-8C1AED94-E6A7-4EB8-9C3D-D1B6F4893E32Q33780776-49A3DFEA-F8A1-42D5-9A2D-40C3397590FCQ33788002-DB144B8D-DD15-4A12-8918-AE59773A3153Q33927508-DC1CE1EE-0BC9-4E98-86FB-58106D99F240Q34056261-B20B3595-2F14-48A5-A387-01344FA694B8Q34368512-68F22133-1CA9-423D-A7AB-F38C230D87C8Q34494645-096B9CEA-3D41-4CE9-8DAD-EEEAF6FDB60DQ34506992-7A80E997-7ABC-4BC0-944D-AE3C72CD73CFQ34638842-B6016B72-D760-4655-900C-2395B81583D0Q34685511-166D4FA2-F78C-4202-915A-5D4232EBEB04Q34770179-E4DFCE25-D991-4042-8A8F-ABB6534A71F6Q34774581-DF6853A0-A22E-4D3C-9406-E3F97F9F1238Q34822475-F1E0C98B-A26D-4815-87B0-B8F2F620F70FQ34939590-9AB193D0-FDAE-4BB9-8C6B-547C37B702E7Q35054336-8B82E5B8-D30B-47BD-A59F-69565B073E10Q35122859-79D12A51-E09F-4370-97EA-E2894B5FE3A4Q35606973-01351080-84C5-4D5C-BDF1-28288E959713Q35610317-E6E862D5-A3E9-4A27-ABEB-0C84F0C7DD43Q35661403-ACBBD6E6-5B9A-4AD0-8EA3-B89C75D4AB1CQ35762966-65540A5E-9D49-4A44-A0AC-68F862016956Q35767516-BCE9645D-B5E0-40F1-AD96-1F8CC7503630
P2860
Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Pharmacologic rescue of confor ...... he treatment of human disease.
@ast
Pharmacologic rescue of confor ...... he treatment of human disease.
@en
type
label
Pharmacologic rescue of confor ...... he treatment of human disease.
@ast
Pharmacologic rescue of confor ...... he treatment of human disease.
@en
prefLabel
Pharmacologic rescue of confor ...... he treatment of human disease.
@ast
Pharmacologic rescue of confor ...... he treatment of human disease.
@en
P2093
P2860
P1433
P1476
Pharmacologic rescue of confor ...... he treatment of human disease.
@en
P2093
Alfredo Ulloa-Aguirre
Jo Ann Janovick
P Michael Conn
Shaun P Brothers
P2860
P304
P356
10.1111/J.1600-0854.2004.00232.X
P577
2004-11-01T00:00:00Z